Despite the tremendous progress in the clinical management of autoimmune diseases,
many patients do not respond to the currently used treatments. Autoreactive B cells play a …

Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

Background: B-cell depletion with rituximab is commonly used for patients with systemic
lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable …

Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE
inception cohort. Methods. Patients in the Systemic Lupus International Collaborating Clinics …

The principle of treating-to-target has been successfully applied to many diseases outside
rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic …

In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60 …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …

Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind,
placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …